



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden



Nikolaos G. Papadopoulos, MD, PhD, FRCP, FAAAAI^{a,b}, Adnan Custovic, MSc, DM, MD, PhD, FRCP^c, Antoine Deschildre, MD^d, Alexander G. Mathioudakis, MD, MRCP(UK)^{a,e}, Wanda Phipatanakul, MD, MS^f, Gary Wong, MD, FRCPC, FHKAM^g, Paraskevi Xepapadaki, MD, PhD^b, Ioana Agache, MD^h, Leonard Bacharier, MDⁱ, Matteo Bonini, MD, PhD^{j,k}, Jose A. Castro-Rodriguez, MD^l, Zhimin Chen, MD, PhD^m, Timothy Craig, MDⁿ, Francine M. Ducharme, MD, MSc, FRCPC^o, Zeinab Awad El-Sayed, MD, PhD^p, Wojciech Feleszko, MD^q, Alessandro Fiocchi, MD^r, Luis Garcia-Marcos, MD, PhD^{s,t}, James E. Gern, MD^u, Anne Goh, MD^v, René Maximiliano Gómez, MD, PhD^{w,x}, Eckard H. Hamelmann, MD, PhD^y, Gunilla Hedlin, MD, PhD^z, Elham M. Hossny, MD, PhD, FAAAAI^{aa}, Tuomas Jartti, MD^{bb}, Omer Kalayci, MD^{cc}, Alan Kaplan, MD, CCFP(EM), FCFP^{dd}, Jon Konradsen, MD, PhD^{ee,ff}, Piotr Kuna, MD, PhD^{gg}, Susanne Lau, MD, PhD^{hh}, Peter Le Souef, MBBS, FRACP, FERS, MDⁱⁱ, Robert F. Lemanske, MD, FAAAAI^{jj}, Mika J. Mäkelä, MD, PhD^{kk}, Mário Morais-Almeida, MD, MSc, PhD^{ll}, Clare Murray, MBChB, MD, MRCP, MRCPHCH^{mm}, Karthik Nagaraju, MDⁿⁿ, Leyla Namazova-Baranova, MD, PhD^{oo}, Antonio Nieto Garcia, MD, PhD^{pp}, Osman M. Yusuf, MD^{qq}, Paulo M.C. Pitrez, MD, PhD^{rr}, Petr Pohunek, MD, PhD, FCCP^{ss}, Cesar Fireth Pozo Beltrán, MD^{tt,uu}, Graham C. Roberts, DM, FRCPC, MA, MSc^{vv}, Arunas Valiulis, MD, PhD^{ww}, and Heather J. Zar, MD, PhD^{xx}; **Pediatric Asthma in Real Life Collaborators*** Manchester, London, Edinburgh, and Southampton, United Kingdom; Athens, Greece; Lille, France; Boston, Mass; Sha Tin, Hong Kong; Brasov, Romania; Rome, Italy; Zhejiang, China; State College, Pa; Montréal, QC, Canada; Cairo, Egypt; Warsaw and Lodz, Poland; Murcia and Valencia, Spain; Madison, Wis; Chicago, Ill; Salta, Argentina; Bielefeld and Berlin, Germany; Solna and Stockholm, Sweden; Turku and Helsinki, Finland; Ankara, Turkey; Edmonton, AB, Canada; Crawley, WA, Australia; Lisbon, Portugal; Chennai, Tamilnadu, India; Moscow, Russia; Porto Alegre, Brazil; Prague, Czech Republic; La Paz and Mexico City, Mexico; Vilnius, Lithuania; and Cape Town, South Africa

What is already known about this topic? Coronavirus disease 2019 has a mild disease course in children and adolescents. Chronic respiratory conditions, including asthma, have been suggested as risk factors; however, asthma in children is highly variable in both triggers and severity.

What does this article add to our knowledge? During the pandemic, pediatric asthma services limited consultations and established virtual clinics. However, respondents perceived their patients' asthma control to be retained or even improved, while treatment adherence was considered increased. Children with asthma were not disproportionately affected by coronavirus disease 2019.

How does this study impact current management guidelines? Trigger avoidance and treatment adherence can rapidly improve asthma control in children, even under lockdown pressure. Children/adolescents with asthma do not appear to need additional prophylactic measures from coronavirus disease 2019 when asthma is well-treated.

^aDivision of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom

^bAllergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece

^cDepartment of Paediatrics, Imperial College London, London, United Kingdom

^dPediatric Pulmonology and Allergy Department, Hôpital Jeanne de Flandre, Lille, France

^eNorth West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

^fChildren's Hospital Boston, Pediatric Allergy and Immunology, Boston, Mass

^gDepartment of Pediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong

^hAllergy & Clinical Immunology, Transylvania University, Brasov, Romania

ⁱDivision of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University, St Louis, Mo

^jDepartment of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli – IRCCS, Rome, Italy

^kNational Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom

^lDivision of Pediatrics, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

^mPulmonology Department, Children's Hospital Zhejiang University School of Medicine, Zhejiang, China

ⁿDepartment of Allergy and Immunology, Penn State University, State College, Pa

^oDepartment of Pediatrics, University of Montréal, Department of Social and Preventive Medicine, University of Montréal, Montréal, QC, Canada

^pPediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt

^qDepartment of Pediatric Respiratory Diseases and Allergy, The Medical University of Warsaw, Warsaw, Poland

Abbreviations used

COVID-19- coronavirus disease 2019

IQR- interquartile range

SARS-CoV-2- severe acute respiratory syndrome coronavirus 2

BACKGROUND: It is unclear whether asthma may affect susceptibility or severity of coronavirus disease 2019 (COVID-19) in children and how pediatric asthma services worldwide have responded to the pandemic.

OBJECTIVE: To describe the impact of the COVID-19 pandemic on pediatric asthma services and on disease burden in their patients.

^fAllergy Department, Bambino Gesù Children's Hospital, Rome, Italy

^gPediatric Respiratory and Allergy Units, "Virgen de la Arrixaca" Children's University Clinical Hospital, University of Murcia, Murcia, Spain

^hInstitute for Biomedical Research of Murcia, IMIB-Arrixaca, & Network of Asthma and Adverse and Allergic Reactions (ARADYAL), Murcia, Spain

ⁱDepartment of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis

^jDepartment of Internal Medicine, Rush Medical College, Chicago, Ill

^kResearch & Education, Ayre Foundation, Salta, Argentina

^lAllergy & Asthma Department, Alas Medical Institute, Salta, Argentina

^mChildren's Center Bethel, EvKB, University Bielefeld, Bielefeld, Germany

ⁿPaediatric Allergy, Centre for Allergy Research, Karolinska Institutet, Solna, Sweden

^{oo}Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt

^{pp}Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland

^{qq}Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey

^{rr}Family Physician Airways Group of Canada, Edmonton, AB, Canada

^{ss}Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

^{tt}Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

^{uu}Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland

^{vv}Charité Universitätsmedizin Berlin, Pediatric Pulmonology, Immunology and Intensive Care Medicine, Berlin, Germany

^{ww}School of Paediatrics & Child Health, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Crawley, WA, Australia

^{xx}Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis

^{yy}Department of Allergy, Helsinki University Central Hospital, Helsinki, Finland

^{zz}Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal

^{aaa}Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom

^{bbb}VN Allergy & Asthma Research Centre, Chennai, Tamilnadu, India

^{ccc}Pediatric Department, Pirogov Russian National Research Medical University, the Ministry of Health, Moscow, Russia

^{ddd}Pediatric Pulmonology & Allergy Unit, Children's Hospital la Fe, Valencia, Spain

^{eee}Allergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom

^{fff}Pediatric Pulmonology Division, Hospital Moinhos de Vento, Porto Alegre, Brazil

^{ggg}Pediatric Pulmonology, Pediatric Department, 2nd Faculty of Medicine, Charles University, Prague, University Hospital Motol, Prague, Czech Republic

^{hhh}Teaching and Research Department and Paediatric Allergy Department, Hospital with Specialties Juan María de Salvatierra, La Paz, Baja California Sur México, La Paz, Mexico

ⁱⁱⁱAllergy & Immunology Department, Hospital Infantil de Medico Federico Gomez, Mexico City, Mexico

^{jjj}Paediatric Allergy and Respiratory Medicine within Medicine at the University of Southampton, Southampton, United Kingdom

^{kkk}Clinic of Children's Diseases, Institute of Clinical Medicine, Medical Faculty of Vilnius University, Vilnius, Lithuania

^{lll}Department of Pediatrics & Child Health, MRC Unit on Child & Adolescent Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa

* Pediatric Asthma in Real Life Collaborators: Rola Abou Taam, Hugo Azuara, Jacques Brouard, Pierrick Cros, Cindy De Lira, Jean-Christophe Dubus, Teija Dunder, Kamilla Efendieva, Carole Egron, Andrzej Emeryk, Yunuen R. Huerta Villalobos, Nidia Karen, Pascal Le Roux, Julia Levina, Monica Medley, Major Nagaraju, Daniela Rivero Yeveerino, Marja Ruotsalainen, Stanley Szeffer, Cyril

Schweitzer, Berenice Velasco Benhumea, Rosalaura Villarreal, Laurence Weiss, and Anna Zawadzka-Krajewska.

This study was supported by the Respiratory Effectiveness Group (REG). REG has received support from AstraZeneca, Novartis, and Sanofi for continued work on Pediatric Asthma in Real Life. A.G.M. was supported by the National Institute of Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC).

Conflicts of interests: J. Konradsen reports grants from Region Stockholm, during the conduct of the study. N. G. Papadopoulos reports personal fees from ALK, Novartis, Nutricia, HAL, Menarini/FAES Farma, Sanofi, Mylan/MEDA, Biomay, AstraZeneca, GlaxoSmithKline (GSK), MSD, ASIT BIOTECH, and Boehringer Ingelheim and grants from Gerolymatos International SA and Capricare, outside the submitted work. A. Custovic reports personal fees from Novartis, Regeneron/Sanofi, Thermo Fisher Scientific, Boehringer Ingelheim, and Philips, outside the submitted work. A. Deschildre reports grants and personal fees from Stallergenes Greer and personal fees from Novartis, ALK, Teva, GSK, MEDA-MYLAN, CHIESI, Alimmune, DBV Technologies, and Astra Zeneca, outside the submitted work. A. G. Mathioudakis reports grants from Boehringer Ingelheim, outside the submitted work. W. Phipatanakul reports grants from the National Institutes of Health (NIH); grants and personal fees from Genentech/Novartis and Sanofi/Regeneron; personal fees from GSK; and nonfinancial support from Thermo Fisher, Lincoln Diagnostics, Alk Abello, and Monaghan, outside the submitted work. P. Xepapadaki reports personal fees from Nutricia, Nestle, Friesland, Uriach, Novartis Pharma AG, and GSK, outside the submitted work. L. Bacharier reports personal fees from Aerocrine, GSK, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia, outside the submitted work. T. Craig reports grants and personal fees from CSL Behring, Dyax, Takeda, BioCryst, and Pharming; personal fees from Grifols; and grants and nonfinancial support from GSK, Regeneron, and Novartis/Genentech, outside the submitted work. F. M. Ducharme reports grants from Thorasys Inc; personal fees from Jean-Coutu Pharmaceuticals; and nonfinancial support from Novartis Canada, and Trudell Medical, outside the submitted work. J. E. Gern reports grants from NIH/National Institute of Allergy and Infectious Diseases; personal fees from Regeneron, Ena Therapeutics, and MedImmune, outside the submitted work; and personal fees and stock options from Meissa Vaccines Inc, outside the submitted work. A. Kaplan reports personal fees from Astra Zeneca, Behring, Boehringer Ingelheim, Covis, GSK, NovoNordisk, Novartis, Grifols, Pfizer, Sanofi, Teva, and Trudell, outside the submitted work. P. Kuna reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca, Berlin Chemie Menarini, Hal, Lekam, Mylan, Novartis, Polpharma, and Teva, outside the submitted work. R. F. Lemanske reports grants from the NIH, Clinical and Translational Science Award (NIH), Childhood Origins of ASThma, and AsthmaNet; nonfinancial support from GSK, Boehringer Ingelheim, Merck, Teva, and the American Academy of Allergy, Asthma & Immunology; and personal fees from LSU, Elsevier, UpToDate, the University of Kentucky, ThermoFischer, and Food Allergy Research and Education Network, outside the submitted work. C. Murray reports personal fees from Novartis, GSK, Astra Zeneca, Thermo Fisher, and Boehringer Ingelheim, outside the submitted work. P. M. C. Pitrez reports grants from AstraZeneca, Chiesi, and Teva and personal fees from Astra Zeneca, Teva, Novartis, Mundipharma, S&D Pharma, and GSK, outside the submitted work. G. C. Roberts reports personal fees from ALK, Allergen Therapeutics, Meda Plus, and Merck; and a patent for the use of sublingual immunotherapy to prevent the development of allergy in at-risk infants, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication May 8, 2020; revised May 25, 2020; accepted for publication June 1, 2020.

Available online June 17, 2020.

Corresponding author: Nikolaos G. Papadopoulos, MD, PhD, FRCP, FAAAAI, Division of Infection, Immunity & Respiratory Medicine, The University of Manchester, Royal Manchester Children's Hospital, Oxford Road, Manchester, UK M13 9WL. E-mail: ngpallergy@gmail.com.

2213-2198

© 2020 American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2020.06.001>

METHODS: An online survey was sent to members of the Pediatric Asthma in Real Life think tank and the World Allergy Organization Pediatric Asthma Committee. It included questions on service provision, disease burden, and the clinical course of confirmed cases of COVID-19 infection among children with asthma.

RESULTS: Ninety-one respondents, caring for an estimated population of more than 133,000 children with asthma, completed the survey. COVID-19 significantly impacted pediatric asthma services: 39% ceased physical appointments, 47% stopped accepting new patients, and 75% limited patients' visits. Consultations were almost halved to a median of 20 (interquartile range, 10-25) patients per week. Virtual clinics and helplines were launched in most centers. Better than expected disease control was reported in 20% (10%-40%) of patients, whereas control was negatively affected in only 10% (7.5%-12.5%). Adherence also appeared to increase. Only 15 confirmed cases of COVID-19 were reported among the population; the estimated incidence is not apparently different from the reports of general pediatric cohorts.

CONCLUSIONS: Children with asthma do not appear to be disproportionately affected by COVID-19. Outcomes may even have improved, possibly through increased adherence and/or reduced exposures. Clinical services have rapidly responded to the pandemic by limiting and replacing physical appointments with virtual encounters. © 2020 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2020;8:2592-9)

Key words: Asthma; Children; Virus; Adherence; COVID-19; SARS-CoV2; Control

INTRODUCTION

The ongoing coronavirus disease 2019 (COVID-19) pandemic, induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is driving an unprecedented international research and clinical mobilization, to understand and contain the disease.¹ COVID-19 has less direct impact on children and adolescents than on adults, although all ages are affected.² In children, as in adults, preexisting chronic conditions appear to increase the risk for severe or fatal disease.^{3,4} Despite initial clinical reports that did not identify asthma to be over-represented among patients with COVID-19,⁵ it has been suggested that asthma, particularly when uncontrolled, may be included among the underlying conditions imposing a risk for severe COVID-19.³ Further evaluation is urgently required, because children with wheezing illness/asthma constitute a significant proportion throughout the pediatric age span and asthma is the most frequent chronic condition managed by pediatricians.^{6,7}

To rationalize management and instruct the public health care system, it is crucial to understand whether asthma, allergy, or their treatments add risk, protect, or have no discernible effects on the health of children with asthma.^{8,9}

Symptoms of COVID-19 in children usually include dry cough and often fever. In contrast with infected adults, most infected children appear to have a milder clinical course.¹⁰ Dyspnea may be present; however, wheeze has not been reported as part of the clinical presentation.^{2,11,12} There is

currently no published information about the clinical course or other characteristics of COVID-19 in children with asthma. In parallel, the COVID-19 pandemic introduced a need to change clinical practice, including minimizing face-to-face contact and limiting the use of aerosolising procedures.¹³ A need for guidelines in the context has been expressed¹⁴; however, this is challenged by the lack of evidence.

In this context, pediatric asthma services around the world are being reorganized to face the new, uncertain, reality. Pediatric Asthma in Real Life, a think tank initiated by the Respiratory Effectiveness Group, comprising pediatric asthma experts from all around the world, aims to develop recommendations that will improve patient care.¹⁵ To identify and share best practices, and in collaboration with the World Allergy Organization Pediatric Asthma Committee, we assessed the impact of COVID-19 on pediatric asthma services and their patients through a survey addressed to large pediatric asthma clinics worldwide.

METHODS

An online questionnaire was constructed with input from the Pediatric Asthma in Real Life steering group. It included questions about the operation of pediatric asthma clinics during the COVID-19 pandemic, changes in the methods used to communicate with and assess patients, estimates of overall disease activity and patient attitudes, as well as known cases of COVID-19 infection, within the respondents' pediatric asthma cohorts. The survey questionnaire can be found in Table E1 in this article's Online Repository at www.jaci-inpractice.org. Sixty-two members of the participating groups, actively involved in the assessment and management of children with asthma, as assessed by a previous survey,¹⁵ and representing clinical services in different health care systems, were invited to complete the survey on April 9, 2020. The recipients were allowed to further forward the survey to additional clinical practices in their country. Because of the extraordinary circumstances and urgency, the allowed response time was 10 days; no reminders were sent.

Responses are presented descriptively, as proportions or median (interquartile range [IQR]) for numeric variables. We report pertinent differences in the responses across different responder groups:

- A. Participants from countries with different COVID burden: (1) less than 10 deaths per million population (limited burden), (2) between 10 and 100 deaths per million population (intermediate burden), and (3) more than 100 deaths per million population (high burden), as of April 19, 2020, the last day of the survey.
- B. Participants from different continents. Adequate responses were collected from the Americas, Asia, and Europe, which allowed meaningful comparisons.
- C. Participants from countries with different economies. Countries with high versus low and middle income, according to the World Bank classification.
- D. Participants from different practice settings, namely, primary care/private clinics, secondary care, and tertiary/university hospitals.

We used Fisher exact test for comparing dichotomous data, given the relatively limited number of participants in each group. Kruskal-Wallis test was used for comparing continuous data, assuming a non-normal distribution. Between-group differences were formally tested only for findings around asthma control and treatment adherence, to avoid multiple comparisons and the risk of type 1 and/or type 2 statistical error. In an exploratory analysis, we extrapolated the

estimates of respondents about asthma control, treatment changes, and treatment adherence in their actual case numbers during the preceding month and we present the risk ratios of patients with favorable versus unfavorable outcomes. Given the limitations of this analysis, we chose to use the 99% CIs.

Although completion of questions was optional, each question was answered by more than 75% of the eligible participants for that question. Missing responses data were disregarded when evaluating the findings.

RESULTS

Survey responses and patient population represented

All invited responded to the survey; response from additional centers, invited by the participants, led to an overall response rate of 146% over the original invitations. Ninety-one experts, each representing a different clinical practice from different care settings, economies, and countries, including the whole spectrum of COVID-19 disease burden, completed the survey. Respondents were from 27 countries and 5 continents (Africa, Asia, Americas, Europe, and Oceania), consulting a median of 20 (IQR, 10-25) children with asthma per week, corresponding to 89,804 annual visits in the 61 centers reporting this question, or an estimated 133,969 visits in the complete cohort. Characteristics of the respondent's practices are summarized in [Tables I and II](#) and in [Tables E2 to E4](#) in this article's Online Repository at www.jaci-inpractice.org.

Effect of the COVID-19 pandemic on pediatric asthma practices worldwide

Over the recent time period, pediatric asthma clinics across the world have markedly changed their practice because of the COVID-19 pandemic ([Table I](#)). Almost half the participants (47%) reported that their clinics did not accept/receive new patients during the epidemic, with responders from Asia being a notable exception, as 78% received new patients. Among the participating practices, 39% have ceased physical appointments; this proportion exceeded 60% in the more heavily burdened countries. Among centers that continued to run physically, 75% reported a decrease in the number of evaluated cases during the pandemic period. During the month preceding the completion of the survey, participants reviewed a median of 35 cases (IQR, 20-60), approximately half their normal rate, in parallel to the escalating measures to avoid patient contact.

In pediatric asthma clinics that continued accepting physical appointments, several practice changes were implemented to minimize these encounters. Further to the reduction of evaluated cases, most (62%) clinics limited the frequency of planned monitoring encounters, with 28% reviewing only children with severe asthma, while 8% accepted only patients receiving biologics. Access to asthma medications was an issue in 30% of the participating centers, predominantly in Asia (44%).

Importantly, more than 90% of participating centers have launched virtual online or telephone consultations to substitute or complement clinical visits, while 73% have used a helpline to address the needs of their patients. About half the participants considered virtual visits a suboptimal clinical encounter, viable only in the short-term. Nevertheless, a considerable proportion (42%) found them acceptable, or, occasionally, as good as

face-to-face visits. Several tools were used by all respondents to facilitate better distal monitoring of asthma control. Validated tools for evaluating asthma control, such as the Asthma Control Test or the Asthma Control Questionnaire, were used by 72% of the participants. Peak expiratory flow readings (31%) or portable spirometer readings (8.5%) were less often used, while treatment adherence was formally monitored in 42% of practices. Symptom recording apps or telemedicine platforms were used in 27% of centers.

There were some between-group differences in monitoring. First, validated asthma control questionnaires were less favored in private/primary care practices (33%), compared with proportions exceeding 80% in secondary, tertiary, and university hospitals. On the contrary, 67% of the private practices opted for telemedicine platforms, in contrast to only 28% of the clinics in secondary care and 13% of the university/tertiary care hospitals. Peak expiratory flow rate was more often used in less affluent countries (42% in low-/middle- vs 27% in high-income countries), while portable spirometers were solely available in high-income countries. Treatment adherence was more extensively evaluated in Asia (78%), than in Europe (44%), or in the Americas (16%).

Pediatric asthma burden during the COVID-19 pandemic

Evaluation on pediatric asthma burden during the pandemic was queried as proportions improving, remaining stable, or worsening within each individual clinic, for a number of clinically relevant aspects ([Table II](#)). Within each practice, a median of 70% (IQR, 60%-80%) of evaluated patients were well controlled, 20% (IQR, 10%-30%) partially controlled, and 10% (IQR, 0%-10%) uncontrolled. In subjectively evaluating their patients' asthma control status, participants considered that while in 85% (IQR, 70%-100%) of cases this was in line with their previous symptom trajectories (as expected), in 20% (IQR, 10%-40%) this exceeded their expectations, while control had deteriorated in only 10% (IQR, 7.5%-12.5%). The risk ratio of the children with better than expected versus worse than expected asthma control was 2.69 (99% CI, 2.17-3.34), while all subgroup analyses yielded consistent findings. Apart from the pre-specified subgroup analyses (by the countries' COVID-19 burden, countries' economy, continent, and clinical setting), we evaluated separately centers using or not using a validated questionnaire for evaluating asthma control and centers formally evaluating treatment adherence or not. In line with this impression of the clinical status, no treatment changes were required for 80% of patients (IQR, 60%-90%), while a similar proportion of patients (~10%) required treatment escalation or deescalation. Treatment adherence was estimated to be unchanged in 80% (IQR, 60%-100%) of patients, whereas it improved in 20% (IQR, 10%-40%) of children with asthma, especially in the Americas (IQR, 20%-63%). Reduced adherence was reported in only up to 10% of patients (IQR, 0%-10%). Increased treatment adherence was consistently observed both in the overall study population (relative risk, 1.97; 99% CI, 1.66-2.33) and in all the subgroup analyses.

Countries that were less severely hit by the COVID-19 epidemic reported a higher proportion of well-controlled patients. However, there were no between-group differences in the expected symptom trajectories.

TABLE I. Effects of the COVID-19 pandemic on pediatric asthma practices

Pediatric asthma clinics metrics	Overall cohort	COVID-19 burden (deaths/million)			Clinical setting		
		<10	10-100	>100	Primary	Secondary	Tertiary/university
No. of participants in each category, N	91	31	15	26	15	11	47
Measures to limit physical contact							
Did not receive/accept new cases during pandemic	33/70 (47)	13/25 (52)	6/15 (40)	13/25 (52)	5/15 (33)	7/11 (64)	20/40 (50)
Ceased physical appointments	35/91 (39)	11/31 (35)	4/15 (27)	16/26 (62)	8/15 (53)	3/11 (27)	21/47 (45)
Reduced no. of cases*	39/52 (75)	15/20 (75)	9/11 (82)	8/10 (80)	6/7 (86)	5/8 (63)	21/26 (81)
Reduced planned monitoring visits*	32/52 (62)	12/20 (60)	8/11 (73)	5/10 (50)	6/7 (86)	5/8 (63)	14/26 (54)
Only monitoring patients receiving biologics	6/71 (9)	1/25 (4)	0/15 (0)	3/25 (12)	1/15 (7)	0/11 (0)	4/40 (10)
Only monitoring children with severe asthma	20/71 (28)	4/25 (16)	7/15 (47)	8/25 (32)	2/15 (13)	2/11 (18)	15/40 (38)
Nonphysical services launched to address health needs							
Launched virtual online or telephone consultations	79/87 (91)	25/31 (81)	15/15 (100)	25/26 (96)	15/15 (100)	11/11 (100)	40/47 (85)
Launched helpline for children with asthma	57/78 (73)	23/31 (74)	10/15 (67)	19/26 (73)	11/15 (73)	9/11 (82)	33/47 (70)
Shared any advisory material	45/78 (58)	22/31 (71)	6/15 (40)	13/26 (50)	11/15 (73)	8/11 (73)	23/47 (49)
Shared advisory material via email	24/78 (31)	8/31 (26)	4/15 (27)	11/26 (42)	5/15 (33)	4/11 (33)	14/47 (30)
Shared advisory material via social media	18/78 (23)	12/31 (39)	2/15 (13)	1/26 (4)	4/15 (27)	6/11 (55)	5/47 (11)
Shared advisory material through Web site	14/78 (18)	7/31 (23)	1/15 (7)	3/26 (12)	3/15 (20)	2/11 (19)	7/47 (15)
Tools for evaluating asthma control							
Using at least 1 tool for evaluating asthma control	71/71 (100)	25/25 (100)	15/15 (100)	25/25 (100)	15/15 (100)	11/11 (100)	40/40 (100)
A validated questionnaire, such as ACT or ACQ	51/71 (72)	16/25 (64)	11/15 (73)	20/25 (80)	5/15 (33)	9/11 (82)	33/40 (83)
A standardized questionnaire	19/71 (27)	4/25 (16)	5/15 (33)	9/25 (36)	1/15 (7)	1/11 (9)	16/40 (40)
Peak flow meter reading	22/71 (31)	10/25 (40)	6/15 (40)	4/25 (16)	5/15 (33)	4/11 (36)	11/40 (28)
Portable spirometer reading	6/71 (9)	0/25 (0)	3/15 (20)	1/25 (4)	0/15 (0)	0/11 (0)	4/40 (10)
Diary cards	5/71 (7)	2/25 (8)	2/15 (13)	0/25 (0)	0/15 (0)	0/11 (0)	4/40 (10)
Symptom-recording applications or telemedicine platforms	19/71 (27)	10/25 (40)	4/15 (27)	3/25 (12)	10/15 (67)	3/11 (28)	5/40 (13)
Adherence evaluation	30/71 (42)	9/25 (36)	7/15 (47)	10/25 (40)	5/15 (33)	4/11 (36)	17/40 (43)
Acceptability of virtual clinics							
As good as face-to-face clinics	3/71 (4)	1/25 (4)	1/15 (7)	0/25 (0)	2/15 (13)	0/11 (0)	1/40 (3)
Somehow compromised, but still acceptable	27/71 (38)	8/25 (32)	6/15 (40)	11/25 (44)	4/15 (27)	3/11 (28)	18/40 (45)
Only viable for a short period of time	34/71 (48)	12/25 (48)	7/15 (47)	12/25 (48)	7/15 (47)	5/11 (46)	19/40 (48)
Unsatisfactory, low-quality medical advice	3/71 (4)	2/25 (8)	1/15 (7)	0/25 (0)	1/15 (7)	1/11 (9)	1/40 (3)

ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test.

Values are n (%).

*Among those with physical appointments.

TABLE II. Pediatric asthma burden during the COVID-19 pandemic

Pediatric asthma burden	Overall cohort	COVID-19 burden (deaths/million)			P	Clinical setting			P
		<10	10-100	>100		Primary	Secondary	Tertiary	
No. of participants contributing data, N	61	22	10	23		13	9	34	
Asthma control: What percentage of your pediatric asthma patients are currently									
Well controlled	70 (60-80)	80 (70-90)	70 (60-85)	60 (50-80)	<.01	80 (80-90)	70 (65-80)	70 (60-80)	
Partially controlled	20 (10-30)	20 (10-20)	20 (15-30)	20 (20-30)		20 (10-20)	20 (20-35)	20 (10-30)	
Uncontrolled	10 (0-10)	10 (0-10)	10 (0-10)	10 (10-20)		0 (0-10)	10 (10-15)	10 (10-13)	
Asthma control: How does the current control of your patients compare with your expectations for these patients?									
Better than expected	20 (10-40)	30 (10-50)	20 (10-25)	20 (10-40)		35 (20-43)	25 (10-48)	20 (10-30)	
As expected	85 (70-100)	90 (65-100)	80 (70-95)	80 (70-100)		90 (65-100)	90 (75-100)	80 (70-100)	
Worse than expected	10 (8-13)	10 (0-10)	10 (10-10)	10 (10-20)		0 (0-8)	10 (3-18)	10 (10-20)	.03
Risk ratio of better vs worse asthma control, RR (99% CI)	2.69 (2.17-3.34)	5.19 (3.06-8.81)	2.90 (1.89-4.47)	1.99 (1.50-2.64)		12.67 (5.29-30.32)	4.00 (1.30-12.33)	2.07 (1.65-2.61)	
What proportion of your patients required a change in their asthma treatments?									
Treatment escalation	10 (10-30)	10 (10-30)	10 (10-20)	20 (10-25)		10 (10-30)	15 (10-30)	10 (10-30)	
Unchanged treatment	80 (60-90)	80 (60-90)	80 (80-85)	80 (60-90)		90 (70-90)	80 (65-90)	80 (60-90)	
Treatment de-escalation	10 (0-20)	10 (0-20)	10 (0-10)	10 (0-20)		10 (0-10)	10 (5-15)	10 (0-20)	
Risk ratio escalation vs deescalation, RR (99% CI)	1.41 (1.21-1.65)	1.78 (1.27-2.50)	5.21 (3.15-8.60)	0.95 (0.79-1.16)		2.22 (1.52-3.25)	2.42 (1.05-5.55)	1.24 (1.04-1.47)	
Have you observed changes in the adherence to controller medications?									
Increased adherence	20 (10-43)	20 (10-30)	25 (13-38)	30 (10-50)		30 (20-45)	10 (8-15)	20 (10-50)	
Unchanged adherence	80 (60-100)	90 (70-100)	80 (60-100)	70 (53-100)		70 (65-95)	100 (95-100)	80 (50-100)	.03
Reduced adherence	10 (0-10)	10 (0-10)	10 (5-10)	10 (0-30)		10 (3-10)	0 (0-3%)	0 (0-18%)	
Risk ratio of increased vs reduced adherence, RR (99% CI)	1.97 (1.66-2.33)	3.00 (2.01-4.47)	3.79 (2.41-5.98)	1.43 (1.16-1.77)		3.11 (2.08-4.64)	6.00 (0.38-94.23)	1.73 (1.43-2.09)	
Limited availability/access to asthma medications, n (%)	21/69 (30)	8/25 (32)	2/15 (33)	9/25 (36)		6/15 (40)	3/11 (28)	12/42 (29)	

Values are median (IQR) unless otherwise indicated.

COVID-19 among children with asthma within the participating centers

Suspected cases of COVID-19 in children with asthma were reported in only 13 of 91 participating centers (14%). There were 100 such cases (a median of 3 suspected cases in each of these centers; IQR, 2-10). Of these, only 15 (15%) were confirmed, 10 in 1 center in Italy, 2 in Portugal, and the remaining in 2 French centers. The most frequent presenting symptoms of the confirmed cases included nasal discharge or blockage and cough, whereas breathlessness, fever, and wheeze were less often reported (see details in [Table E5](#) in this article's Online Repository at www.jaci-inpractice.org). Half the reported cases also experienced nonrespiratory symptoms, such as myalgia and fatigue. Eleven of these children (73%) experienced a mild clinical syndrome, 3 (20%) a moderate illness, and only 1 case (6.7%) required hospitalization. None required an admission to the intensive care unit or ventilation, and all made a complete recovery.

DISCUSSION

There is no doubt that pediatric asthma clinics are among health care services significantly affected by the COVID-19 pandemic. The number of new patients evaluated is restricted, while there is also a reduction in the frequency and/or the total number of patients monitored. In addition, use of several diagnostic modalities, including lung function testing, fractional exhaled nitric oxide, or methacholine tests, is limited, along with therapeutic interventions, such as nebulized treatments.¹⁶ However, many services have actively responded to these challenges, most often by "virtual" clinics or other telehealth appliances, which flourished in all medical specialties during the COVID-19 epidemic.¹⁷ Clinicians consider such clinics suboptimal, nonetheless adequate for the, hopefully, short time period under lockdown. Standard tools such as the Asthma Control Test or the Asthma Control Questionnaire were used, whereas objective measures, such as spirometry or peak expiratory flow rate, were less often feasible. The observed approaches are consistent with recent ad-hoc recommendations.¹⁸

Despite the above challenges, there was no apparent deterioration in asthma in the large majority of patients. In fact, based on the perceptions of the participants, improvement exceeded expectations in 20% of subjects. This was accompanied, and possibly partially mediated, by increased adherence to treatment plans—normally a major challenge in pediatric asthma management. Contrasting and very often unproven information has been circulated through the media in regard to maintenance medications and management. Among others, inhaled and/or systemic corticosteroids have been of particular interest, as both a potential COVID-19 treatment and as an increased susceptibility factor.¹⁹ Our findings suggest that parents of children with asthma monitored in specialist clinics have responded to messages on the need for treatment continuation, rather than unfounded fears about potentially detrimental effects of inhaled steroids. Furthermore, social distancing, sheltering at home, and reduced school days may reduce exposure to the main triggers of acute asthma events, most notably rhinovirus infections, outdoor allergens, physical exercise, and air pollution,^{20,21} contributing to sustained, or even improved, outcomes during this period. Nevertheless, a small proportion of children (~10%) have

deteriorated; confinement in children sensitized to indoor allergens and/or psychological factors may have contributed to this.

Despite the differences between countries regarding COVID-19 infection and policies, the number of pediatric patients with asthma with suspected and, even more, confirmed COVID-19 was small, coming mostly from 1 tertiary center in Italy. It is noteworthy that even in these cases, the clinical course was benign, and wheezing, the hallmark of asthma, was observed in only 40%, while the simultaneous presence of other viruses was not assessed.

Our data cannot provide a concrete estimate of the clinically relevant COVID-19 incidence among children with asthma. However, taking into account (1) the reported COVID-19 incidence in the more severely affected countries (the United States, Spain, Italy, France, and the United Kingdom; 2.2-4.8 cases per thousand population²²) and (2) data suggesting that COVID-19, severe enough to lead to seeking medical advice and thus diagnosed, is about 12.8 times less frequent in children than in adults,³ 17 to 38 such cases per 100,000 of a nonselected pediatric population can be assumed. This is consistent with recent data on the burden of COVID-19 in children in China, South Korea, and the United States, where it is uniformly very low.^{3,23,24} In our survey, the estimated population of pediatric patients with asthma represented within these countries was 20,000 to 40,000; that is, the expected range of potential patients with COVID-19 would be 3 to 15, suggesting that COVID-19 is not associated with severe asthma exacerbations.

It is possible that SARS-CoV-2 does not induce bronchial hyperreactivity and asthma-like pathophysiology; nevertheless, this does not exclude the possibility of children with asthma, particularly uncontrolled asthma, developing more severe COVID-19, as we have previously reported for influenza.²⁵ Furthermore, the impact of atopy on SARS-CoV-2 susceptibility needs to be further evaluated, in light of recent findings suggesting that allergic sensitization and allergen exposure may reduce the SARS-CoV-2 receptor, angiotensin-converting enzyme 2.²⁶ However, only 1 case requiring hospitalization was identified through this survey, drawing information from a large number of children with asthma, including a large proportion with severe asthma, given the large proportion of respondents from tertiary centers. Further evaluation of children with asthma, poor symptom control, and high severity in regard to the individual response to SARS-CoV-2 will be needed to draw a firm conclusion.

There are several limitations to this survey. Most importantly, the clinical data that are described are not based on direct evaluation of patients, but on the subjective evaluation of the respondents and therefore, there is a risk of recall bias. In addition, respondents might have been unaware of some of the acute presentations of their patients to alternative clinical sites. However, clinicians are well aware of this issue that is not specific to the COVID-19 era. There is a chance that changes in clinical practice due to COVID-19 may have led more patients to seek medical advice from alternative sources; however, all participating centers offered either physical or virtual appointments or helplines for patients with acute symptoms.

In parallel, children with asthma tend to have less controlled disease at the time of the initial referral to the expert clinic. Therefore, the significant decrease in new referrals may partially account for the respondents' perception that asthma control has improved during the pandemic. However, clinicians were

specifically asked to compare their perceptions about disease control among patients during monitoring visits, during versus before the epidemic. As a result of these limitations, all findings described about the clinical burden of COVID-19 on children with asthma should be considered exploratory and further studies directly evaluating the clinical course of children with asthma are needed.

Moreover, responders are clinicians with high expertise and interest in the domain; therefore, they may not be representative of all pediatric asthma services. Nevertheless, our findings of limited COVID-19 burden within the included cohorts that are potentially selective for children with more severe or uncontrolled asthma, including patients treated with biologics, further supports our conclusions. Moreover, expertise and increased interest, as confirmed by the rapid response of the totality of invited, may also be considered a strong point. Input came from a wide geographical spread; unfortunately, Africa and Oceania were minimally represented. Similarly, the responses do not include many low-income countries, in which health services, underlying susceptibility to illness, and disease impact may be different.

CONCLUSIONS

Children with asthma do not appear to be disproportionately affected by COVID-19; relevant high-end services have rapidly responded, medication adherence has not been negatively affected, and outcomes are promising. Ongoing epidemiological studies, including one initiated by this group, will be able to quantify any added and long-term risk of COVID-19 on children with asthma.

Acknowledgment

The authors thank Mrs Maria Kritikou for excellent administrative support of the survey.

REFERENCES

1. Cook DJ, Marshall JC, Fowler RA. Critical illness in patients with COVID-19: mounting an effective clinical and research response. *JAMA* 2020;323:1559-60.
2. Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. *Infection* 2020;48:445-52.
3. CDC COVID-19 Response Team. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:422-6.
4. Tagarro A, Epalza C, Santos M, Sanz-Santaufemia FJ, Otheo E, Moraleda C, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain [published online ahead of print April 8, 2020]. *JAMA Pediatr*. <https://doi.org/10.1001/jamapediatrics.2020.1346>.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72-314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323:1239-42.
6. Papadopoulos NG, Čustović A, Cabana MD, Dell SD, Deschildre A, Hedlin G, et al. Pediatric asthma: an unmet need for more effective, focused treatments. *Pediatr Allergy Immunol* 2019;30:7-16.
7. Selby A, Munro A, Grimshaw KE, Cornelius V, Keil T, Grabenhenrich L, et al. Prevalence estimates and risk factors for early childhood wheeze across Europe: the EuroPrevall birth cohort. *Thorax* 2018;73:1049-61.
8. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020;146:110-8.
9. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. *Respir Investig* 2020;58:155-68.
10. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. Chinese pediatric novel SARS-CoV-2 infection in children. *Coronavirus Study Team*. *N Engl J Med* 2020;382:1663-5.
11. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of Covid-19 in children in early January 2020 in Wuhan, China. *N Engl J Med* 2020;382:1370-1.
12. Stower H. Clinical and epidemiological characteristics of children with COVID-19. *Nat Med* 2020;26:465.
13. Levin M, Morais-Almeida M, Ansotegui IJ, Bernstein J, Chang YS, Chikhladze M, et al. Acute asthma management during SARS-CoV2-pandemic 2020. *World Allergy Organ J* 2020;13:100125.
14. Dayal D. We urgently need guidelines for managing COVID-19 in children with comorbidities. *Acta Paediatr* 2020;109:1497-8.
15. Mathioudakis AG, Custovic A, Deschildre A, Ducharme FM, Kalaayci O, Murray C, et al. Research priorities in pediatric asthma: results of a global survey of multiple stakeholder groups by the Pediatric Asthma in Real Life (PeARL) think tank. *J Allergy Clin Immunol Pract* 2020;8:1953-1960.e9.
16. Iramain R, Castro-Rodriguez JA, Jara A, Cardozo L, Bogado N, Morinigo R, et al. Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: randomized clinical trial. *Pediatr Pulmonol* 2019;54:372-7.
17. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. *N Engl J Med* 2020;382:1679-81.
18. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. *J Allergy Clin Immunol Pract* 2020;8:1477-1488.e5.
19. Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? *Ecancelmedscience* 2020;14:1023.
20. Niespodziana K, Borochova K, Pazderova P, Schleuderer T, Astafyeva N, Baranovskaya T, et al. Toward personalization of asthma treatment according to trigger factors. *J Allergy Clin Immunol* 2020;145:1529-34.
21. Eguiluz-Gracia I, Mathioudakis AG, Bartel S, Vijverberg SJH, Fuertes E, Comberiat P, et al. The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma [published online ahead of print January 9, 2020]. *Allergy*. <https://doi.org/10.1111/all.14177>.
22. Worldometer. Coronavirus update (live). Available from: <https://www.worldometers.info/coronavirus/>. Accessed May 20, 2020.
23. Korean Society of Infectious Diseases, Korean Society of Pediatric Infectious Diseases, Korean Society of Epidemiology, Korean Society for Antimicrobial Therapy, Korean Society for Healthcare-associated Infection Control and Prevention, Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. *J Korean Med Sci* 2020;35:e112.
24. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. *Pediatrics* 2020;145:e20200702.
25. Guibas GV, Tsolia M, Christodoulou I, Stripeli F, Sakkou Z, Papadopoulos NG. Distinction between rhinovirus-induced acute asthma and asthma-augmented influenza infection. *Clin Exp Allergy* 2018;48:536-43.
26. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. *J Allergy Clin Immunol* 2020;146:203-6.

ONLINE REPOSITORY

TABLE E1. Survey questions and response options

Q1. Does your Pediatric Asthma clinic continue to run physically?
Yes
No
Q2. Has the number of evaluated cases changed in the last month?
Increased
Stable
Decreased
Q3. Has the planned monitoring frequency of patients changed?
No
More frequently
Less frequently
Currently unstable/unknown
Q4. Do you offer a virtual (online or telephone) clinic/consultation?
Yes
No
Q5. In the last few weeks, has the number of evaluated cases
Increased?
Remain stable?
Decreased?
Q6. Approximately how many patients do you see per week (number)?
Number: _____
Q7. Has the type/severity/priority of patients changed?
No
Yes—more severe
Yes—patients receiving biologicals only
Yes—other priority please specify
Q8. Which of the following methods do you use to monitor your patients?
A standardized questionnaire
An asthma control test (ACT, ACQ, other)
Peak flow meter reading
Portable spirometer reading
Adherence evaluation
Diary cards
Symptom-recording app/telemedicine platform
Other (please specify)
Q9. What has been your experience with your virtual clinic so far?
As good as the face-to-face clinic
Somehow compromised but still okay
Only viable for a short period of time
Unsatisfactory—low-quality medical service
Other (please specify): _____
Q10. Do you offer a helpline for your pediatric asthma patients?
Yes
No
Q11. If you do not offer physical or virtual clinic, please describe expectations/plans around pediatric asthma patients in the near future.
Free text: _____
Q12. Do you actively send advice to your asthma patients?
No

(continued)

TABLE E1. (Continued)

By email
Through social media
Through website
Q13. In the last few weeks have you received any new patients?
No
Yes—a few
Yes—several
Q14. If yes, how many new patients do you receive every week, during the COVID-19 pandemic?
Number: _____
Q15. In your asthma clinic, do you have any patients receiving biologicals?
Yes
No
Q16. If yes, how many?
Number: _____
Q17. Do they continue their regular dosage?
Yes
No—stopped
No—reduced frequency
Q18. Has any of your pediatric asthma patients had confirmed COVID?
No
Yes
Q19. If yes, approximately how many?
Number: _____
Q20. Their symptoms at presentation included:
Runny/blocked nose. Percentage: _____
Cough. Percentage: _____
Wheeze. Percentage: _____
Shortness of breath. Percentage: _____
Fever. Percentage: _____
Nonrespiratory symptoms/other. Percentage: _____
Q21. Their clinical course in regard to their asthma has been:
Mild. Percentage: _____
Moderate (treated at home). Percentage: _____
Severe exacerbation (emergency visit or hospital admission). Percentage: _____
Required ICU admission or intubation. Percentage: _____
Death. Percentage: _____
Q22. Has any of your pediatric asthma patients had suspected, but not confirmed COVID?
No
Yes
Q23. If yes, approximately how many?
Number: _____
Q24. Their symptoms at presentation included:
Runny/blocked nose. Percentage: _____
Cough. Percentage: _____
Wheeze. Percentage: _____
Shortness of breath. Percentage: _____
Fever. Percentage: _____
Nonrespiratory symptoms/other. Percentage: _____
Q25. Their clinical course in regard to their asthma has been:
Mild. Percentage: _____
Moderate (treated at home). Percentage: _____

(continued)

TABLE E1. (Continued)

Severe exacerbation (emergency visit or hospital admission). Percentage: _____
Required ICU admission or intubation. Percentage: _____
Death. Percentage: _____
Q26. In the last month, approximately how many patients have you monitored (either physically or virtually)?
Number: _____
Q27. From the patients you have monitored, what is the proportion with Well-controlled asthma. Percentage: _____
Partially controlled asthma. Percentage: _____
Uncontrolled asthma. Percentage: _____
Q28. How does this compare with your expectations for the same patients?
As expected. Percentage: _____
Better than expected. Percentage: _____
Worse than expected. Percentage: _____
Q29. What was the proportion of patients with regard to treatment changes?
Increased treatment. Percentage: _____
Continued treatment. Percentage: _____
Decreased treatment. Percentage: _____
Q30. Is availability or access to medication an issue?
Yes
No
Q31. Have you observed changes in adherence to controller medications?
No changes in adherence. Percentage: _____
Increased adherence. Percentage: _____
Reduced adherence. Percentage: _____
Any comment on adherence changes? _____
Q32. Number of your patients (approximately) who have suffered an exacerbation during the last month and treated at outpatients (independent of COVID)?
Number: _____
Q33. Number of your patients (approximately) who have suffered an exacerbation during the last month and were hospitalized (independent of COVID)?
Number: _____
Q34. In which country do you practice?
Q35. In what setting do you practice?
Tertiary/university hospital
Secondary hospital
Primary care
Community center
Q36. Your email (optional)
Q37. Your name (optional)

ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; ICU, intensive care unit.

TABLE E2. Respondents by country of practice

Continent Country	N
Europe	39
Czech Republic	1
Finland	4
France	11
Germany	2
Greece	1
Italy	2
Lithuania	1
Poland	7
Portugal	1
Romania	1
Spain	2
Sweden	1
United Kingdom	5
Asia	9
China	2
India	2
Pakistan	1
Russian Federation	2
Singapore	1
Turkey	1
Americas	22
Argentina	1
Brazil	1
Canada	2
Chile	1
Mexico	12
United States	5
Africa, Oceania	2
Egypt	1
Australia	1
Undeclared	19

TABLE E3. Respondent distribution by domain

Domains	Participants
Setting	Tertiary/university hospital (47) Secondary care (11) Primary care, private practice (15) Not declared (18)
COVID burden	<10 deaths per million population (31) 10-100 deaths per million population (15) >100 deaths per million population (26) Not declared (19)
Country income (World Bank)	High income (49) Upper middle income (19) Low middle income (4) Not declared (19)

TABLE E4. Pediatric patients with asthma reviewed by the participating centers, in the past and during the COVID-19 pandemic

Patients reviewed	Overall cohort	COVID-19 burden (deaths/million)			Clinical setting		
		<10	10-100	>100	Primary	Secondary	Tertiary
No. of consultations per respondent per week, median (IQR)	20 (10-25)	12.5 (5-20)	18 (14-28)	20 (10-25)	20 (10-25)	5 (5-10)	20 (11-24)
No. of participants contributing data, N	61	22	10	23	13	9	34
Total no. of patients evaluated weekly by respondents, N	1,727	326	301	785	292	69	1081
Annualized estimate of patients evaluated, N	89,804	16,952	15,652	40,820	15,184	3,588	56,212
No. of patients evaluated per respondent during the preceding month, median (IQR)	35 (20-60)	25 (10-40)	38 (21-60)	48 (20-68)	50 (10-100)	25 (10-30)	40 (20-60)
No. of participants contributing data, N	59	22	14	22	13	9	37
Total no. of patients evaluated during the preceding month by participants, N	3,593	820	728	1,925	870	214	2,509
Annualized estimate of patients evaluated, N	43,116	9,840	8,736	23,100	10,440	2,568	30,108
No. of new patients per respondent per week, during COVID-19, median (IQR)	5 (3-9)	3.5 (2-5)	4 (3-6)	5 (3-10)	5 (2-8)	4 (4-5)	5 (3-10)
No. of participants contributing data, N	27	10	4	9	8	2	14
Total no., N	194	63	20	74	62	8	97
No. of patients receiving biologics in the clinic, median (IQR)	11 (5-20)	5 (3-10)	9 (5-15)	20 (10-30)	10 (5-17)	3 (3-3)	11 (6-20)
No. of participants contributing data, N	38	8	9	20	4	1	32

TABLE E5. Clinical presentation of children with asthma and confirmed COVID-19

Symptoms	No. (proportion)
Nasal discharge or blockage	9 of 15 (60%)
Cough	11 of 15 (73%)
Wheeze	6 of 15 (40%)
Breathlessness	6 of 15 (40%)
Fever	6 of 15 (40%)
Nonrespiratory symptoms	9 of 15 (60%)